Compare AbCellera Biologics Inc (ABCL) vs GXO Logistics Inc (GXO) Price & Performance

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

GXO Logistics trades at $47.85, up 1.9% in the last session, with a bearish technical signal but strong analyst backing. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6 billion in 2026. However, margins remain tight, with a net income margin of 0.96%, and the P/E ratio of 41.3 suggests high valuation relative to earnings.

The outlook is mixed: bullish analyst consensus, with 88.9% buy ratings and a $65.67 price target, indicates potential upside, but stagnant margins and bearish technicals pose risks. Investors should weigh strong business wins against cost absorption challenges highlighted in recent earnings reports.